drg dhea, 96 wells
to add this product to your interest list, sign up or login.
- drg international inc.
- dhea, 96 wells
block scientific is the right laboratory equipment supplier to approach for all kinds of new and refurbished lab equipment. we offer the dhea, 96 wells from drg international inc. for a competitive price. the drg dhea elisa is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of dehydroepiandrosterone (dhea) in serum.
drg dhea elisa kit
– follows competitive binding principle
this elisa kit is a quality, reliable product, based on the principle of competitive binding.
for in vitro diagnostic use only
- kit components – standard (standard 0–5), microtiterwells, enzyme conjugate, stop solution, substrate solution, wash solution
- storage – when stored at 2-8°c unopened reagents will retain reactivity until expiration date.
summary and explanation
dehydroepiandrosterone (dhea; androstenolone; 3β-hydroxy-5-androsten-17-one) is a c19 steroid produced in the adrenal cortex and, to a lesser extent, gonads. dhea serves as a precursor in testosterone and estrogen synthesis. due to the presence of a 17-oxo (rather than hydroxyl) group, dhea has relatively weak androgenic activity, which has beenestimated at ~10% that of testosterone. however in neonates, peripubertal children and in adult women, circulating dhea levels may be several-fold higher than testosterone concentrations, and rapid peripheral tissue conversion to more potent androgens (androstenedione and testosterone) and estrogens may occur. moreover, dhea has relatively low affinity for sex-hormone binding globulin. these factors may enhance the physiologic biopotency of dhea.
the physiologic role of dhea has not been conclusively defined. a variety of in vitro effects, including antiproliferative effects in different cell lines and effects on enzyme-mediated cell metabolism, have been reported. in vivo studies suggest that dhea may affect cholesterol and lipid metabolism, insulin sensitivity and secretion and immune function. abnormal dhea levels have been reported in schizophrenia and obesity. therapeutic administration of dhea has been proposed for several conditions, including obesity and cardiovascular disease.
serum dhea levels are relatively high in the fetus and neonate, low during childhood, and increase during puberty. increased levels of dhea during adrenarche may contribute to the development of secondary sexual hair. serum dhea levels progressively decline after the third decade of life. no consistent changes in serum dhea levels occur during the menstrual cycle or pregnancy; however, parity may lower serum dhea levels in premenopausal women.
dhea has a rapid metabolic clearance rate as compared to its sulfated conjugate, dhea-s. because of this, serum dhea levels are 100-1000 fold lower than dhea-s levels. in addition, serum dhea levels show significant diurnal variation which is dependent on adrenocorticotrophic hormone (acth). serum dhea levels increase in response to exogenous acth administration.
measurement of serum dhea is a useful marker of adrenal androgen synthesis. abnormally low levels may occur in hypoadrenalism, and elevated levels occur in several conditions; including virilizing adrenal adenoma and carcinoma, 21-hydroxylase and 3β-hydroxysteroid dehydrogenase deficiencies and in some cases of female hirsutism. since very little dhea is produced by the gonads, measurement of dhea levels may aid in the localization of androgen source in virilizing conditions.